Spondyloarthritis

Long-Term Effects of Secukinumab on Fatigue in Ankylosing Spondylitis

Study authors assessed the long-term effects of secukinumab on fatigue in patients with ankylosing spondylitis in the MEASURE 1 and MEASURE 2 trials.

Unmet Pain Management Needs Are Evident in Axial Spondyloarthritis

Investigators compared differences in pain reports between patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis to assess how pain sensitivity was associated with disease and health outcomes.

High IL-17 Levels Linked to Decreased Psoriatic Arthritis Risk

Researchers determined the causal associations between genetically predicted TNF-α, IL-12p70, and IL-17 levels and risk for psoriatic arthritis.

Enthesitis, Spinal Mobility Key Disability Drivers in axSpA

Investigators examined the long-term association between disease activity and disability in axSpA.

Increased Risk for Bone Fractures in Patients With Psoriatic Diseases

For adults with psoriatic diseases, the likelihood of developing bone fractures is increased.

Osteoarthritis Risk Higher Among Patients With Psoriatic Arthritis Than Psoriasis Alone

Researchers assessed the risk for osteoarthritis in patients with PsA compared with those with psoriasis and the general population.

Psoriatic Arthritis and Rheumatoid Arthritis Have Similar Effect on Hand Function

Researchers compared the effect of psoriatic arthritis and rheumatoid arthritis on objective and subjective parameters of hand function.

Inflammatory Burden High in Patients With Early Peripheral Spondyloarthritis

Researchers evaluated the prevalence of axial involvement in early peripheral spondyloarthritis and whether inflammation predicted relapse on treatment withdrawal.

Disease Activity Linked to Radiographic Progression in Axial Spondyloarthritis

Study authors determined the association between disease activity and the subsequent 2-year spinal radiographic progression in axial spondyloarthritis.

FDA to Review High-Concentration Biosimilar of Adalimumab

The FDA has accepted for review the BLA for AVT02 (Alvotech), a proposed biosimilar to adalimumab; AbbVie, with high concentration (100mg/mL) dosage forms.